Reminder: GLP-1 receptor agonists interactions with oral contraception – safety guidance
Pharmacy owners providing the Pharmacy Contraception Service are reminded that the Faculty of Sexual & Reproductive Healthcare (FSRH) advises that individuals use contraception whilst using Glucagon-like peptide-1 (GLP-1) agonists, with additional advice for those using tirzepatide.
The statement from the FSRH can be found at: FSRH statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception (Feb 2025) | FSRH
The FSRH has also produced a patient leaflet to assist with communicating the advice to patients.
The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its public guidance confirming that all individuals of child-bearing potential (who are able to become pregnant) using GLP-1 medications should take steps to ensure they do not become pregnant.
